

Co-pay Program



Together with
GSK Oncology



BLENREP
belantamab
mafodotin-blmf
for injection 100 mg

Starting a new treatment brings up a lot of questions. One question may be how you will pay for your medicine. **Together with GSK Oncology** understands how stressful this can be, so we've created a co-pay program to help make GSK medicines more affordable for eligible patients.



WHAT DOES IT COVER?*

- Helps with the patient's cost share up to a total of \$26,000 for up to 12 months
- Covers up to \$100 per visit toward the patient's cost of product administration

*If a patient is approved, the Co-pay Program may help with the patient's cost share for the GSK product and the cost of administration, up to \$100 per administration for intravenous products, up to a program total of \$26,000 annually. Residents of Massachusetts, Michigan, Minnesota, or Rhode Island are not eligible for reimbursement of administration fees. Doctor's office visits, labs, and other ancillary services are not included in the Co-pay Program.

AM I ELIGIBLE?

You may be eligible if you:

- Have a commercial medical or prescription insurance plan OR are uninsured
- Are a resident of the US (including the District of Columbia, Puerto Rico, and the US Virgin Islands)



You are not eligible if you:

- Are enrolled in Medicare
- Have a medical or prescription insurance plan that is funded by state or federal government
 - For example, Medicare, Medicaid, VA, or TRICARE
- Are enrolled in a commercial health plan that does not permit the use of co-pay assistance programs

BLENREP is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called BLENREP REMS.

Please see accompanying full Prescribing Information, including BOXED WARNING and Medication Guide.

Together with GSK Oncology must let you know if you are eligible. See back page to learn how to apply. Please visit [TogetherwithGSKOncology.com](https://www.togetherwithgskoncology.com) for full terms and conditions.

Co-pay Program



Together with
GSK Oncology



BLENREP
belantamab
mafodotin-blmf
for injection 100 mg

HOW DO I SIGN UP?

You will need to enroll in **Together with GSK Oncology** to find out if you are eligible for the Co-pay Program.

1. Ask your healthcare provider to help you complete the **Together with GSK Oncology** Enrollment Form
2. Your healthcare provider will fax the form to us
3. **Together with GSK Oncology** will call you within 1 to 2 business days to go over your options for benefits

Be sure to promptly return any phone calls you receive from **Together with GSK Oncology**.

HOW DO I USE THE DEBIT CARD?*

Once you're enrolled in the Co-pay Program, you will receive a debit card and welcome letter in the mail. Be sure to bring your card with you to your treatments.



1. Submit your Explanation of Benefits

Your insurance plan will send you an Explanation of Benefits (EOB) after each visit. You or your healthcare provider must fax your EOB to the number on the top of your Enrollment Form after each treatment. **Together with GSK Oncology** will review your EOB for approval.

2. Receive funds on your debit card

If your EOB submission is approved, you will receive funds on your card to cover your share of the cost and administration fee for intravenous products (if eligible). We will let you know the amount loaded on your card by mail.

3. Pay your healthcare provider

Once the funds are on your card, you can now pay your healthcare provider for your treatment. Bring your card to your healthcare provider's office to make your payment.

*Doctor's office visits, labs, and other ancillary services are not included in the Co-pay Program.

BLENREP is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called BLENREP REMS.

Please see accompanying full Prescribing Information, including BOXED WARNING and Medication Guide.

Have questions or want more information?

Call us at 1-844-4GSK-ONC (1-844-447-5662)

Monday-Friday (8 AM to 8 PM ET)

Trademarks are property of their respective owners.



©2020 GSK or licensor.
BLMBROC190004 August 2020
Produced in USA. 0002-0007-58